Brazilija - portugalų - ANVISA (Agência Nacional de Vigilância Sanitária)

fundaÇÃo oswaldo cruz - ribavirina - antiviroticos

Europos Sąjunga - portugalų - EMA (European Medicines Agency)

accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. exceto em recém-diagnosticados lmc em fase crónica, não há ensaios clínicos controlados demonstrando um benefício clínico ou aumento da sobrevivência para essas doenças. .

Europos Sąjunga - portugalų - EMA (European Medicines Agency)

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. o efeito de imatinib no resultado do transplante de medula óssea não foi determinado. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. a experiência com imatinib em pacientes com mds/mpd associadas com rearranjos do gene pdgfr é muito limitado. não há ensaios clínicos controlados demonstrando um benefício clínico ou aumento da sobrevivência para essas doenças.

Brazilija - portugalų - ANVISA (Agência Nacional de Vigilância Sanitária)

laboratÓrios pfizer ltda - tensirolimo - antineoplasico

Brazilija - portugalų - ANVISA (Agência Nacional de Vigilância Sanitária)

wyeth indÚstria farmacÊutica ltda - tensirolimo - antineoplasico

Brazilija - portugalų - ANVISA (Agência Nacional de Vigilância Sanitária)

wyeth indÚstria farmacÊutica ltda - tensirolimo - antineoplasico

Europos Sąjunga - portugalų - EMA (European Medicines Agency)

koanaa healthcare gmbh - o imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - agentes antineoplásicos - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. os pacientes que têm um baixo ou muito baixo risco de recorrência não deve receber tratamento adjuvante. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. exceto em recém-diagnosticados lmc em fase crónica, não há ensaios clínicos controlados demonstrando um benefício clínico ou aumento da sobrevivência para essas doenças.

Europos Sąjunga - portugalų - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - agentes antineoplásicos - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Europos Sąjunga - portugalų - EMA (European Medicines Agency)

amgen technology (ireland) uc - bevacizumab - carcinoma, renal cell; peritoneal neoplasms; ovarian neoplasms; breast neoplasms; carcinoma, non-small-cell lung; fallopian tube neoplasms - agentes antineoplásicos - mvasi em combinação com a quimioterapia à base de fluoropirimidina é indicado para o tratamento de pacientes adultos com carcinoma metastático do cólon ou reto. mvasi em combinação com paclitaxel é indicado para o tratamento de primeira linha de doentes adultos com cancro da mama metastático. para mais informações sobre o status do receptor do fator de crescimento epidérmico humano (her2), consulte a seção 5. mvasi, além de platina-base de quimioterapia, é indicado para o tratamento de primeira linha de pacientes adultos com metastáticos avançada, metastático ou recorrente de células não-pequenas de câncer de pulmão diferente predominantemente de células escamosas de histologia. mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. mvasi, em combinação com carboplatin e o paclitaxel é indicado para o tratamento de pacientes adultos com avançadas (federação internacional de ginecologia e obstetrícia (figo) fases iii-b, iii-c, iv) epitelial de ovário, trompas de falópio, ou primário peritoneal câncer. mvasi, em combinação com carboplatin e gemcitabine ou em combinação com carboplatin e paclitaxel, é indicado para o tratamento de pacientes adultos com a primeira recorrência da platina-sensível epiteliais do ovário, da trompa de falópio ou peritoneal primário de câncer que não receberam terapêutica prévia com bevacizumabe ou outros inibidores de vegf ou do receptor de vegf-alvo agentes. mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents. mvasi, em combinação com paclitaxel e cisplatina ou, em alternativa, paclitaxel e topotecan em pacientes que não podem receber platina terapia, é indicado para o tratamento de pacientes adultos com persistente, recorrente ou metastático, o carcinoma do colo do útero.

Brazilija - portugalų - ANVISA (Agência Nacional de Vigilância Sanitária)

glaxosmithkline brasil ltda - zidovudina, lamivudina - antiviroticos (inibe replicacao virotica)